Merck   3Q Revenues: $11.0 billion (-4%) 3Q Earnings: $1.1 billion (-35%) YTD Revenues: $32.7 billion (-8%) YTD Earnings: $3.7 billion (-31%) Comments: Pharmaceutical sales were down 4% to $9.5 billion in the quarter, impacted by a 2% negative impact due to foreign exchange and loss of exclusivity for Singulair (-53% to $280 million), Maxalt (-76% to $40 million), Temodar (-29% to $162 million) and Cozaar/Hyzaar (-20% to $238 million). Remicade sales were up 17% to $574 million. Gardasil sal...